|
|
|
 |
 |
|
|
|
|
|
|
|
 |
|
GROUP 1
In Vitro Activity of Macrolides, Azalides, Streptogramins
GROUP 2
In Vitro Activity and Resistance Profiles of Ketolides
GROUP 3
Demonstration of Activity of the MASKO Compounds in Animal
and In Vitro Models
GROUP 4
Clinical Studies: Respiratory Infections in Adults
GROUP 5
Safety and Efficacy; Clinical Studies: Non-Respiratory
Infections in Adults
GROUP 6
Clinical Studies: Pediatrics
GROUP
7
Resistance Profiles of Macrolides, Azalides, Streptogramins
GROUP
8
In Vitro Activity and Clinical Use of Oxazolidinones
GROUP 9
Pharmacology, Pharmacokinetics and Pharmacodynamics of
the MASKO Compounds
GROUP 10
Highlights of Research on H. Pylori
GROUP 11
Expanding the Potentials for the MASKO Compounds: Asthma,
Atherosclerosis, Cancer and Inflammation |
GROUP
1
In Vitro Activity of Macrolides, Azalides, Streptogramins
1.01
Synthesis and Microbiological
Activity of 17-Membered Azalides (POSTER AVAILABLE)
1.02
The Site of Interaction
of Macrolides with the Ribosome
1.03
Review of In Vitro
Activity of Azithromycin During the Four Years Period
(1995-1998) (POSTER AVAILABLE)
1.04
Susceptibility of
Common Respiratory Tract Pathogens to Penicillins and
Azithromycin in Zagreb, Croatia, 1996-1998 (POSTER AVAILABLE)
1.05
Changing Susceptibilities
of Invasive Streptococcus pneumoniae (Sp) Strains to Penicillin
(Pen), Cefuroxime (Cef), Erythromycin (Ery) and Clarithromycin
(Clari) from 1990 to 1998 in Montreal, Canada (POSTER AVAILABLE)
1.06
In Vitro Susceptibility
Testing of Respiratory Pathogens: Comparison of Susceptibility
Test Methods (POSTER AVAILABLE)
1.07
In Vitro Activity
of Roxithromycin (ROX) and Comparative Macrolides Against
Haemophilus influenzae Isolated from Respiratory Tract
Infections (RTI)
1.08
Activity of Quinupristin/Dalfopristin
(Q/D) Against Gram-Positive Cocci in Africa: Report of
the Global SMART Study
1.09
Activity of Quinupristin/Dalfopristin
(Q/D) Against Gram-Positive Cocci in Europe: Report of
the Global SMART Study
1.10
Global Evaluation
of Quinupristin/Dalfopristin (Q/D) Activity Against 19,852
Gram-Positive Pathogens: Final Report of the Global SMART
Study
1.11
In Vitro Comparative
Antimicrobial Activity of Quinupristin/dalfopristin against
Gram-positive Cocci
1.12
Relative In Vitro
Efficacy of Quinupristin-Dalfopristin in Relationship
with New Fluoroquinolones Towards Gram-Positive, Belgian
Organisms
1.13
Sensitivity of Gram-Positive
Cocci in Hospitalized Patients (POSTER AVAILABLE)
1.14
Activity of Clarithromycin
Against Pathogens of the Respiratory Tract and ENT, and
the Frequency of Mixed Infections (POSTER AVAILABLE)
1.15
In Vitro Susceptibility
Testing of Streptococcus pneumoniae Isolates from a Multi-Center
European Clinical Treatment Trial: Clarithromycin Modified
Release Treatment of the Acute Exacerbation of Chronic
Bronchitis (POSTER AVAILABLE)
1.16
Bactericidal Activity
of Different Antibiotics on Pneumococcal Strains with
Various Degrees of Susceptibility to Penicillin (POSTER AVAILABLE)
1.17
Comparative Activity
of Clarithromycin and Other Antibiotics Against S. pneumoniae
and S. pyogenes in Austria
1.18
Streptococcus pyogenes
Susceptibility to Macrolides in Slovakia: Isolates from
Community Patients (POSTER AVAILABLE)
1.19
Antistaphylococcal
Activity of Quinupristin/ Dalfopristin Alone and in Combination
with Eight Other Antibiotics
1.20
Comparative Activity
of Quinupristin/Dalfopristin (OD) and Vancomycin (VA)
Against Nosocomial Methicillin-Resistant Staphylococcus
aureus (MRSA)
1.21
In Vitro Effects of
Azithromycin on Salmonella typhi: Early Inhibition by
Concentrations Less Than MIC and Reduction of MIC by Alkaline
pH and Small Inocula
1.22
Azithromycin Activity
Against 100 Shigella spp Strains Isolated from Paediatric
Patients in Argentina and Paraguay as Compared to that
of Other Antibacterial Agents
1.23
Susceptibility of
Ureaplasma urealyticum and Mycoplasma hominis to Azithromycin
and Other Antimicrobial Agents In Vitro (POSTER AVAILABLE)
1.24
The Susceptibility
of Mycobacterium avium Complex (MAC) to Clarithromycin,
1991-1999
GROUP 2
In Vitro Activity and Resistance Profiles of Ketolides
2.01
The C-11/12 Carbamate
Side Chain of the Ketolide Antimicrobial Telithromycin
(HMR 3647) Enhances Binding to Both MLS-Sensitive and
-Resistant Ribosomes
2.02
Structure-Activity
Relationship of the Ketolide Telithromycin (HMR 3647)
2.03
Design, Synthesis
and Characterization of ABT-773: A Novel Ketolide Highly
Active against Multidrug Resistant Pathogens (POSTER AVAILABLE)
2.04
Mechanism of Action
for Novel Ketolide ‹ ABT-773 (POSTER AVAILABLE)
2.05
Comparative In Vitro
Activity of ABT-773, a Novel Antibacterial Ketolide and
Macrolide Antibiotics (POSTER AVAILABLE)
2.06
Effect of pH, Serum
and Media on the In Vitro Minimal Inhibitory Concentration
of ABT-773 (POSTER AVAILABLE)
2.07
Quality Control Parameters
for ABT-773 Susceptibility Tests (POSTER AVAILABLE)
2.08
Susceptibility to
Telithromycin and Erythromycin Among Clinical Isolates
of Gram-Positive Pathogens and Reassessment of Disk Diffusion
Test Criteria
2.09
Antipneumococcal Activity
of Telithromycin By 4 Methods
2.10
Lack of In Vitro MLSB
Resistance Induction by the Ketolide Telithromycin (HMR
3647): Role of the 3-Keto Group
2.11
In Vitro Activity
of Telithromycin (HMR-3647) in Comparison to that of agents
of the MAS-KO group and the Glycopeptides against 373
Gram-Positive Recent Clinical Isolates
2.12
Antimicrobial Activity
of ABT-773 (POSTER AVAILABLE)
2.13
Proposal for Macrolide-Lincosamide-Streptogramin
Antibiotic Resistance Determinants (POSTER AVAILABLE)
2.14
In Vitro Studies of
a New Ketolide, ABT-773, Against Multiresistant Gram-Positive
Cocci (POSTER AVAILABLE)
2.15
The In Vitro Activity
of ABT-773 and Other Antimicrobial Agents against Respiratory
Tract Pathogens (POSTER AVAILABLE)
2.16
Time-Kill and Minimum
Bactericidal Activities of ABT-773 against Respiratory
Tract Pathogens (POSTER AVAILABLE)
2.17
The In Vitro Activity
of ABT-773 against Gram-positive Respiratory Pathogens (POSTER AVAILABLE)
2.18
Comparison of the
In Vitro Activity against Respiratory Pathogens of a Novel
Antibacterial Ketolide, ABT-773, with that of Erythromycin
and Ciprofloxacin (POSTER AVAILABLE)
2.19
The In Vitro Activity
of the Ketolides ABT-773 and HMR-3004 Measured by Broth
Microdilution Against Macrolide Susceptible and Macrolide
Resistant Streptococci and Staphylococci (POSTER AVAILABLE)
2.20
Rapid Drug Accumulation
of ABT-773 in Streptococcus pneumoniae (POSTER AVAILABLE)
2.21
In Vitro Selection
of Resistance to Telithromycin (HMR 3647), Clindamycin,
Pristinamycin, and Four Macrolides in Streptococcus pneumoniae
2.22
Macrolide and Ketolide
Resistance in Clinical Strains of Streptococcus pneumoniae:
Mutations in 23S rRNA and L4 Ribosomal Protein (POSTER AVAILABLE)
2.23
The In Vitro Activity
of Telithromycin (HMR 3647) against 817 Isolates of Streptococcus
pneumoniae Collected from 27 Centres Throughout Great
Britain and Ireland during the 1997-1998 Cold Season
2.24
Molecular Basis of
ABT-773 Activity Against erm-Containing Macrolide Resistant
S. pneumoniae (POSTER AVAILABLE)
2.25
Effect of ABT-773
and Other Antimicrobial Agents on the Morphology and the
Release of Interleukin-1ß and Interleukin-8 Against Haemophilus
influenzae and Streptococcus pneumoniae in Whole Blood (POSTER AVAILABLE)
2.26
In Vitro Bactericidal
Activity of ABT-773, a New Ketolide, vs. Clarithromycin,
Azithromycin, Ciprofloxacin, Amoxicillin/ Clavulanate
Against Penicillin/Erythromycin Sensitive and Resistant
S. pneumoniae (SP) and H. influenzae (POSTER AVAILABLE)
2.27
HMR 3647 Demonstrates
Excellent In Vitro Activity against Clinical Isolates
of S. pyogenes and S. pneumoniae with M and MLSB Resistance
Phenotypes
2.28
The In Vitro Activity
of ABT-773 Against Gram-Negative Respiratory Pathogens (POSTER AVAILABLE)
2.29
In Vitro Activity
of ABT-773 against 362 Clinical Isolates of Anaerobic
Bacteria (POSTER AVAILABLE)
2.30
In Vitro Activity
of ABT-773 Against Anaerobic Bacteria Isolated from Bowel
Flora (POSTER AVAILABLE)
2.31
In Vitro Activity
of ABT-773 Against 293 Aerobic and Anaerobic Pathogens
Isolated from Skin and Soft Tissue Animal and Human Bite
Wound Infections (POSTER AVAILABLE)
2.32
In Vitro Activity
of a New Ketolide Antibiotic, ABT-773, Against Chlamydia
pneumoniae (POSTER AVAILABLE)
2.33
Intracellular Activity
and Postantibiotic Effect (PAE) of ABT-773 Against Legionella (POSTER AVAILABLE)
2.34
Intracellular Activity
of ABT-773 and Other Antimicrobial Agents against Legionella
pneumophila Isolates (POSTER AVAILABLE)
2.35
Activity of Telithromycin,
a New Ketolide, Against Human Mycoplasmas
2.36
The In Vitro Activity
of Macrolides and a Ketolide Against Anaerobic Bacteria (POSTER AVAILABLE)
GROUP 3
Demonstration of Activity of the MASKO Compounds in Animal
and In Vitro Models
3.01
Anti-Streptococcal
Effects of Azithromycin and Roxithromycin in an In Vitro
Dynamic Model Simulating the Steady-State Tonsillar Concentrations (POSTER AVAILABLE)
3.02
Flow Cytometric Analysis
of Killing of Streptococcus pneumoniae, Haemophilus Influenzae,
and Staphylococcus aureus by Azithromycin and Clarithromycin
With High and Low Polymorphonuclear (PMN) Cell Concentrations (POSTER AVAILABLE)
3.03
Effect of Clarithromycin
(CL) and Azithromycin (AZ) on Chlamydia pneumoniae (Cpn)
in a Continuous Infection Model (POSTER AVAILABLE)
3.04
Antimicrobial
Effect of Low-Concentration Azithromycin on L. pneumophila
in the Mono Mac 6 In Vitro Infection Model
3.05
Azithromycin (AZI)
for the Treatment of Chlamydial Infections of the Upper
Reproductive Tract (URT) in the Pig-Tailed Macaque Model (POSTER AVAILABLE)
3.06
Experimental Hemophilus
influenzae Pneumonia: Effect of Age and Telithromycin
Therapy
3.07
The Ketolide ABT-773
Protects Against Lethal Toxoplasma gondii Infection (POSTER AVAILABLE)
3.08
Telithromycin: Comparative
Bactericidal Activity and Postantibiotic Effect (PAE)
Against Respiratory Pathogens
3.09
Therapy of Experimental
Otitis Media (EOM) with Telithromycin (HMR 3647): Defining
PK parameter for Microbiologic Success and ŒBreak Pointš
3.10
In Vivo Evaluations
of ABT-773 and HMR-3647 against Respiratory Pathogens
in Murine and Rat Models of Infection (POSTER AVAILABLE)
3.11
Efficacy of ABT-773
against Experimental Bacteremia in Mice Caused by Resistant
Streptococcus pneumoniae (POSTER AVAILABLE)
3.12
ABT-773 and Azithromycin
Against Experimental Pneumonias in Rats Caused by Susceptible
and Resistant Streptococcus pneumoniae (POSTER AVAILABLE)
3.13
Mycoplasma pneumoniae
Infection in a Mouse Pneumonia Model. Impact of Therapy
with Clarithromycin (Clari) (POSTER AVAILABLE)
3.14
Activity of ABT-773
against Mycobacterium avium Complex (MAC) in the Beige
Mouse Model (POSTER AVAILABLE)
3.15
In Vitro Bactericidal
Antagonism of Synercid (SYN) and Beta-Lactams Against
Methicillin-Resistant Staphylococcus aureus (MRSA) Does
Not Predict Treatment Failure in Experimental Endocarditis
(EE) (POSTER AVAILABLE)
3.16
Activities of ABT
773 (Ketolide), HMR 3647 (Ketolide) and Linezolid (Oxazoladinone)
Against Mycobacterium avium (MAC) In Vitro and In Vivo
GROUP
4
Clinical Studies: Respiratory Infections
in Adults
4.01
Assessment of Clinical
Outcomes and Human Fibroblast-binding of Bacteria from
Pneumococcal Pneumonia Patients (POSTER AVAILABLE)
4.02
Treatment of Upper
and Lower Respiratory Tract Infections with Azithromycin
Slovak Prospective Noncomparative Trial (POSTER AVAILABLE)
4.03
Preferences of General
Practitioners in Moscow for 3 or 5 Days Azithromycin Prescriptions
and Treatment Outcomes (POSTER AVAILABLE)
4.04
Azithromycin for Prophylaxis
of Mycoplasma pneumoniae Infections in Military Recruits (POSTER AVAILABLE)
4.05
In Vitro Streptococcus
pneumoniae Resistance: Correlation with Outcomes in Patients
with Respiratory Infections (POSTER AVAILABLE)
4.06
Fingerprinting of
Late Positive Cultures in Mycobacterium avium Complex
Lung Disease Treated With Macrolide Regimens Using Pulsed
Field Gel Electrophoresis
4.07
Clinical and Laboratory
Efficacy of Roxithromycin Treatment of Acute Bacterial
Sinusitis in Adult Outpatients
4.08
Efficacy and Safety
of Roxithromycin in the Treatment of Acute Sinusitis
4.09
Open, Comparative
Study of the Efficacy and Tolerability of Azithromycin
versus Amoxycillin in Acute Rhinosinusitis in Adults
4.10
Post-Marketing Surveillance
Study of Azithromycin (500 mg Tablets) in the Treatment
of Outpatients with Upper Respiratory Tract Infections
(Acute Otitis M, Acute Pharyngitis/Tonsillitis)
4.11
Comparison of Clarithromycin
versus Azithromycin for Bacteriologic Eradication and
Relapse Prevention in Tonsillopharyngitis: A Meta-Analysis (POSTER AVAILABLE)
4.12
Additional Antibiotic
Utilization in a Randomized Trial of Clarithromycin Compared
with Azithromycin for the Treatment of S. pyogenes Pharyngitis/Tonsillitis (POSTER AVAILABLE)
4.13
Single Oral 1.5 g
Azithromycin Dose in the Treatment of Uncomplicated Tonsillitis
In Adults Pilot Study (POSTER AVAILABLE)
4.14
Efficacy and Safety
of Roxithromycin in the Treatment of Bacterial Bronchitis
4.15
Comparison of Clarithromycin
and Loracarbef in the Treatment of Secondary Bacterial
Infections of Acute Bronchitis (POSTER AVAILABLE)
4.16
A Comparative Study
of the Safety and Efficacy of Clarithromycin 500 mg Modified
Release and Amoxicillin 500 mg in the Treatment of Acute
Exacerbation of Chronic Bronchitis (POSTER AVAILABLE)
4.17
Secondary Bacterial
Infection of Acute Bronchitis: Clarithromycin Treatment
Response of Clarithromycin Non-Susceptible Streptococcus
pneumoniae (POSTER AVAILABLE)
4.18
Correlation of Clarithromycin
Treatment Outcome with MIC for Haemophilus influenzae
in Secondary Bacterial Infection of Acute Bronchitis (POSTER AVAILABLE)
4.19
Cost-Effectiveness
of Once-Daily Clarithromycin Compared to Amoxicillin/Claulanic
Acid in the Treatment of Acute Exacerbation of Chronic
Bronchitis (POSTER AVAILABLE)
4.20
A Comparative Study
of the Safety and Efficacy of Clarithromycin 500 mg and
Amoxicillin/Clavulanic Acid in the Treatment of Acute
Exacerbation of Chronic Bronchitis (POSTER AVAILABLE)
4.21
Efficacy of 3-day
Course of Azithromycin (AZM) in the Treatment of Acute
Exacerbations of Chronic Bronchitis (AECB): A Meta-Analysis
4.22
Efficacy and Safety
of Roxithromycin in the Treatment of Community-Acquired
Pneumonia (CAP)
4.23
Efficacy of Levofloxacin
in the Treatment of Community-Acquired Pneumonia Due to
Macrolide-Resistant Streptococcus Pneumoniae
4.24
Levofloxacin Versus
Azithromycin Plus Ceftriaxone in Moderate to Severe Community-Acquired
Pneumonia (CAP)
4.25
Safety and Efficacy
Comparison of Clarithromycin Immediate Release with Trovafloxacin
in Community-Acquired Pneumonia (POSTER AVAILABLE)
4.26
Treatment Outcomes
Associated with Initial Oral and Intravenous Antibiotic
Therapy for Community-Acquired Pneumonia (CAP) in U.S.
Hospitals (POSTER AVAILABLE)
4.27
Macrolide Utilization
in the Treatment of Community-Acquired Pneumonia (CAP)
in US Hospitals (POSTER AVAILABLE)
4.28
Outcomes Associated
with Clarithromycin vs. Routine Treatment in Intravenous
to Oral Switch for Pneumonia (POSTER AVAILABLE)
4.29
The Effect of Early
Initiation of Antimicrobial Therapy in Low to Moderate
Risk Pneumonia Inpatients (POSTER AVAILABLE)
4.30
Timing of Intravenous
to Oral Switch Therapy for Hospitalized Pneumonia: An
Outcomes Evaluation in 41 U.S. Hospitals (POSTER AVAILABLE)
4.31
A Single-Blind, Multicenter
Study of 3 Days Azithromycin versus 7 Days Roxithromycin
in the Treatment of Lower Respiratory Tract Infections
4.32
Clarithromycin Switch-Therapy
in Adult Community Acquired Lower Respiratory Tract Infections (POSTER AVAILABLE)
4.33
Oral Therapy with
Clarithromycin in Hospitalized Patients with Community
Acquired Pneumonia (POSTER AVAILABLE)
4.34
Comparative Clinical
Study of the Tolerability and Efficacy of Two Dosage Regimens
of Azithromycin and Clarithromycin in the Treatment of
Community-Acquired Pneumonia in Adults (Progress Report)
4.35
Empiric Treatment
of Community-Acquired Pneumonia: Slovak Comparative Pharmacoeconomic
Study (POSTER AVAILABLE)
4.36
Azithromycin Versus
Erythromycin for Community Acquired Pneumonia: A Cost-Minimization
Analysis (POSTER AVAILABLE)
4.37
Outcomes and Costs
of Azithromycin Therapy for Patients with Community Acquired
Pneumonia of Various Risk Stratification (POSTER AVAILABLE)
4.38
Clinical Efficacy
of Intravenous Azithromycin Monotherapy in Hospitalized
Patients with Community-Acquired Pneumonia (POSTER AVAILABLE)
4.39
Cost-Effectiveness
of Azithromycin versus Cefuroxime with or without Erythromycin
in the Treatment of Hospitalized Patients with Community-Acquired
Pneumonia (POSTER AVAILABLE)
4.40
Open, Comparative
Study of the Efficacy, Safety and Tolerance of Azithromycin
vs Clarithromycin in the Treatment of Patients with Community
Acquired Pneumonia
4.41
Treatment of Respiratory
Tract Infections (RTI) in Adults with 3 Days of Azithromycin:
A Meta-Analysis
4.42
Post-Marketing Surveillance
Study of Azithromycin (500 mg Tablets) in the Treatment
of Patients with Lower Respiratory Tract Infections
4.43
Efficacy and Toleration
of Once-daily Azithromycin versus Twice-Daily Clarithromycin
in Adult Community-Acquired Pneumonia
4.44
The Use of Step-Down
Therapy in Eligible Patients: The Cost Advantages from
Oral Clarithromycin Therapy (POSTER AVAILABLE)
4.45
Azithromycin in the
Treatment of Atypical Pneumonias: A Review of 454 Cases (POSTER AVAILABLE)
4.46
Clinical and In Vitro
Efficacy of Macrolides in Acute Exacerbation of Chronic
Obstructive Pulmonary Disease (POSTER AVAILABLE)
4.47
Azithromycin (IV/PO)
for Treatment of Community Acquired Pneumonia Caused by
Legionella Pneumophila (POSTER AVAILABLE)
4.48
Serological Diagnosis
of Mycoplasma pneumoniae Pneumonia in Adults Which Test
to Use? (POSTER AVAILABLE)
GROUP
5
Safety and Efficacy; Clinical Studies: Non-Respiratory
Infections in Adults
5.01
Azithromycin Tolerability
in Adult Patients (POSTER AVAILABLE)
5.02
Is Azithromycin Treatment
Associated with the Prolongation of Q-Tc Interval? (POSTER AVAILABLE)
5.03
The Safety of Azithromycin
in the Treatment of Adults with Community-Acquired Infections
5.04
Six Yearsš Experience
in the Global Quinupristin/Dalfopristin Compassionate-Use
Programme for Treatment of Gram-Positive Infections
5.05
Efficacy and Safety
of Treatment of Elderly Patients with Quinupristin/Dalfopristin
5.06
Safety and Efficacy
of Home Parenteral Administration of Synercid (Quinupristin/Dalfopristin)
5.07
APACHE II Score as
a Predictor of Mortality in Patients with Vancomycin-Resistant
Enterococcus faecium Infection Receiving Quinupristin/Dalfopristin
5.08
Quinupristin/Dalfopristin
in the Treatment of Endocarditis with Valvular Vegetation
Due to Staphylococcus aureus
5.09
Efficacy and Safety
of Quinupristin/Dalfopristin (SynercidŽ) for the Treatment
of Bone and Joint Infections in an Ongoing Emergency-Use
Program
5.10
SynercidŽ: Lessons
from Balanced Use at Community Teaching Hospitals
5.11
Efficacy and Safety
of Quinupristin/Dalfopristin (SynercidŽ) for Treatment
of Methicillin-Resistant Staphylococcus aureus Infections
5.12
Methicillin-resistant
Staphylococcus Eradicated from Breast Abscess with Oral
Linezolid after Vancomycin Treatment Had Failed
5.13
Reversible Parasthesias
of Feet, Macrocytosis, Low Vitamin B12 Levels and Minimal
Anemia Complicating Prolonged Linezolid Therapy
5.14
Successful Treatment
of a Recurrent "Late" Lyme-Carditis Using a Combination
Therapy of Roxithromycin and Co-Trimoxazole
5.15
Azithromycin versus
Ciprofloxacin in the Treatment of Diarrhea Caused by Campylobacter
species (POSTER AVAILABLE)
5.16
Azithromycin in the
Treatment of Shigellosis (POSTER AVAILABLE)
5.18
Gastrointestinal Adverse
Event Severity Comparisons with Extended Release Clarithromycin
and Immediate Release Clarithromycin (POSTER AVAILABLE)
5.20
Open, Comparative
Study of the Efficacy, Safety and Tolerance of Azithromycin
vs Amoxicillin/Clavulanic Acid in Dental and Periodontal
Soft Tissue Infections
5.21
PCR Detection of Chlamydia
trachomatis in Material Taken Laparoscopically from Gynaecologic
Patients (POSTER AVAILABLE)
5.22
Economic Burden of
STD in Croatia: Incremental Cost Effectiveness Analysis
of Azithromycin vs. Doxycycline for Treating Chlamydia
trachomatis Genital Infections in Women (POSTER AVAILABLE)
5.23
Macrolides in Treatment
of Chlamydial Diseases
5.24
Azithromycin in the
Management of Women with Chlamydial Cervicitis
5.25
Comparative Analysis
of Azithromycin and Doxycycline Efficacy in the Treatment
of Female Patients with Acute Urethral Syndrome Caused
by Ureaplasma Urealyticum (POSTER AVAILABLE)
5.26
Chlamydial Conjunctivitis
in Contact Lense Carriers: Successful Treatment with Single
Dose Azithromycin (POSTER AVAILABLE)
5.27
Azithromycin in Control
of Trachoma (POSTER AVAILABLE)
5.28
Azithromycin for the
Treatment of Erythema Migrans A Meta Analysis (POSTER AVAILABLE)
5.29
Comparison of Azithromycin
and Doxycycline in the Treatment of Erythema Migrans (POSTER AVAILABLE)
5.30
Azithromycin versus
Tetracyclines in the Treatment of Acne Vulgaris (POSTER AVAILABLE)
5.31
Oral Use of Azithromycin
for the Treatment of Acne Rosacea (POSTER AVAILABLE)
5.32
Azithromycin for Malaria
Prophylaxis and In Vitro Synergy Studies (POSTER AVAILABLE)
5.33
An Open-Label, Randomized,
Comparative Study of IV and Oral Azithromycin (AZ) Alone
or with Metronidazole (MET) vs Doxycycline (DOX)+Cefoxitin
(CEF)+MET+Probenicid (PRO) for the Treatment of Acute
Pelvic Inflammatory Disease (PID) (POSTER AVAILABLE)
GROUP
6
Clinical Studies: Pediatrics
6.01
Influence of Macrolides
on the Normal Flora in Pediatrics: New Data (POSTER AVAILABLE)
6.02
Roxithromycin in the
Treatment of RTI in Children
6.03
Efficacy and Tolerability
of Azithromycin in Treating Children Less than 1 Year
Old with Upper Respiratory Tract Infections
6.04
Efficacy and Safety
of Treatment of Pediatric Patients with Quinupristin/Dalfopristin
6.05
Azithromycin Tolerability
in Children (POSTER AVAILABLE)
6.06
Short-Course Therapy
of Lower Respiratory Tract Infections with a 500 mg Total
Daily Dosage of Clarithromycin: Once Daily vs Twice Daily
Administration (POSTER AVAILABLE)
6.07
Treatment of Children
with Macrolides in Outpatient Clinics
6.08
Patterns of Macrolides
Prescribing in Outpatient Pediatric Departments in Russia
6.09
Clarithromycin Underdosing
of Paediatric Patients in the Community (POSTER AVAILABLE)
6.10
Comparison of Azithromycin
and Co-Amoxiclav in Acute Sinusitis and Acute Otitis Media
in Children (POSTER AVAILABLE)
6.11
Azithromycin vs Comparators
in Treatment of Pediatric Otitis Media
6.12
Azithromycin versus
Clarithromycin: Clinical and Economic Comparison in the
Treatment of Acute Otitis Media in Children (POSTER AVAILABLE)
6.13
3-day vs. 5-day Azithromycin
Course: Clinical Comparative Trial of Efficacy and Safety
in the Treatment of Upper Respiratory Tract Infections
in Children (POSTER AVAILABLE)
6.14
Comparing the Safety
and Efficacy of Clarithromycin with Azithromycin for the
Treatment of Pharyngitis and/or Tonsillitis (POSTER AVAILABLE)
6.15
Streptococcal Pharyngotonsillitis
in Children: Management with Clarithromycin, Azithromycin
and Propicillin (POSTER AVAILABLE)
6.16
Comparative Study
of the Efficacy, Safety and Tolerance of Azithromycin,
Amoxiclav, and Cefaclor as Antibiotic Therapy in Paediatric
Patients with Pharyngo-Tonsillitis
6.17
Clinical and Bacteriological
Efficacy of Various Antibiotics Used for the Treatment
of Streptococcal Pharyngotonsillitis in Italy (POSTER AVAILABLE)
6.18
Randomized Trial of
8-Days Course of Spiramycin vs 10-Days Course of Penicillin
V in Children with Streptococcal Tonsillopharyngitis
6.19
Azithromycin Clinical
Experience in the Treatment of Pertussis Syndrome (POSTER AVAILABLE)
6.20
Comparative Clinical
Study of Azithromycin and Erythromycin in the Treatment
of Pertussis in Children Preliminary Results (POSTER AVAILABLE)
6.21
A Prospective, Randomized,
Single-Blind Study Comparing the Efficacy and Safety of
Clarithromycin vs Erythromycin Estolate in the Treatment
of Pertussis (POSTER AVAILABLE)
6.22
The Tolerance of Prophylactic
Azithromycin Administered During a Hospital-Wide Outbreak
of Pertussis
6.23
Pertussis: Where Do
We Go From Here? (POSTER AVAILABLE)
6.24
Switch Therapy with
Clarithromycin in Community Aquired Pneumonia in Children
6.25
The Etiologic Diagnosis
of Mycoplasma pneumoniae Pneumonia in Children
6.26
Reduced Lung Diffusion
Capacity after Community Acquired Pneumonia due to Mycoplasma
Pneumoniae in Children
6.27
Mycoplasma pneumoniae
and Chlamydia pneumoniae as Aetiological Agents of Recurrent
Respiratory Tract Infections (POSTER AVAILABLE)
6.28
Importance of Mycoplasma
pneumoniae and Chlamydia pneumoniae in Lower Respiratory
Tract Infections in Pediatric Age (POSTER AVAILABLE)
6.29
Etiology of Acute
Lower Respiratory Tract Infections in Hospitalized Infants:
Chlamydia Trachomatis Investigation (POSTER AVAILABLE)
6.30
Azithromycin vs. Ceftriaxone
for the Treatment of Uncomplicated Typhoid Fever in Children
GROUP
7
Resistance Profiles of Macrolides, Azalides, Streptogramins
7.01
The Effect of Increased
Macrolide Consumption on Resistance to Erythromycin (ERY)
and Azithromycin (AZI) among Common Respiratory Pathogens
in Slovenia (POSTER AVAILABLE)
7.02
The Alexander Project:
1998 Prevalence of Resistance and Comparative In Vitro
Activity of Macrolide Antimicrobials against Community-Acquired
Lower Respiratory Tract Isolates of Streptococcus pneumoniae,
Haemophilus influenzae and Moraxella catarrhalis
7.03
Resistance Development
in Respiratory Pathogens Due to Subinhibitory Concentrations
of Azithromycin and Clarithromycin
7.04
Can Erythromycin Resistant
Streptococcus pneumoniae be Treated with a Macrolide? (POSTER AVAILABLE)
7.05
Streptococcus pneumoniae
Resistance in Dubrovnik, 1998
7.06
Analysis of the Distribution
of Macrolide Resistance Determinants of Streptococcus
pneumoniae Clinically Isolated in Spain, Italy and UK
7.07
Prevalence of Macrolide
Resistance Mechanism in Streptococcus pneumoniae from
the U.S. (POSTER AVAILABLE)
7.08
Mechanisms of Clarithromycin
Resistance Among Streptococcus pneumoniae Isolates from
Children and Adults in the Southeastern United States (POSTER AVAILABLE)
7.09
Failure of Macrolide
Therapy in Patients with Bacteremia Due to Macrolide Resistant
Streptococcus pneumoniae
7.10
In Vitro Derived-Macrolide-Resistant
Streptococcus pneumonia Strains Have Ribosomal Mechanism
of Resistance
7.11
A Low Prevalence of
Macrolide-Resistant Streptococcus pneumoniae in Canada:
Results of a 1998/1999 National Respiratory Isolate Surveillance
Study (POSTER AVAILABLE)
7.12
Longitudinal Analysis
of Resistance Among Streptococcus Pneumoniae Isolated
from 96 Geographically Distributed Institutions in the
United States During the 1997-1998 and 1998-1999 Respiratory
Seasons
7.13
Prevalence and Mechanisms
of Macrolide Resistance in Clinical Isolates of Streptococcus
pyogenes in France
7.14
Prevalence of Molecular
Mechanism of Resistance in Clinical Isolates of Streptococcus
pyogenes from Italy and UK
7.15
Group A Streptococcus
Resistance to Macrolides in Quebec: A Provincial Survey. (POSTER AVAILABLE)
7.16
Streptogramin Resistance
Mechanisms in vanA Containing Enterococcus faecium Strains
7.18
Subinhibitory Concentrations
of Synercid (SYN) and Erythromycin (ERY) Decrease the
Expression of Methicillin Resistance in Methicillin-Resistant
Staphylococcus aureus
7.19
Prevalence of Antimicrobial
Resistance among Clinical Isolates of Heamophilus influenzae
and Moraxella catarrhalis (POSTER AVAILABLE)
7.20
Penicillin and Macrolide
Resistance in Streptococcus pneumoniae in Ontario, Canada (POSTER AVAILABLE)
7.21
Decreasing Penicillin
and Macrolide Resistance in Streptococcus pneumoniae in
Canada: Whošs Driving Whom (POSTER AVAILABLE)
7.22
Ascendancy of Erythromycin
Resistance in Streptococcus pneumoniae Associated with
a Change in Antibiotic Prescription Pattern (POSTER AVAILABLE)
7.23
Phenotypic and Genotypic
Characterization of Macrolides-Resistant Group A Streptococcus
Strains in the Province of Quebec, Canada (POSTER AVAILABLE)
7.24
Evolution Of Resistance
In Campylobacter spp To Erythromycin and Other Oral Antimicrobial
Agents From 1987 To 1999
7.25
Erithromycin and Azithromycin
Resistance In Campylobacter spp Strains (POSTER AVAILABLE)
GROUP
8
In Vitro Activity and Clinical Use of
Oxazolidinones
8.01
Antimicrobial Activity
and Spectrum of Linezolid (Formerly U-100766) Tested Against
Nearly 3,000 Strains of Multiple Drug-Resistant, Gram-Positive
Organisms
8.02
Influence of Mechanisms
of Resistance to Antibiotics that Bind to the 50S Ribosomal
Subunit on the Activity of Linezolid Against Gram-Positive
Organisms
8.03
In Vitro Activity
of Linezolid against Selected Gram-Positive Pathogens
8.04
Oxazolidinone Resistance
Mutations in 23S rRNA Identify the Site of the Drug Action
8.05
Activity of Linezolid
(LNZ) Against Gram-Positive Bacteria Including Vancomycin-Resistant
Enterococci (VRE)
8.06
Linezolid is Active
Against Penicillin-Resistant, Macrolide-Resistant and
Ciprofloxacin-Resistant Streptococcus pneumoniae
8.07
Antipneumococcal Activity
of Linezolid Compared to Four Macrolides
8.08
Expression
of Virulence Factors by Gram-Positive Cocci Exposed to
Sub-MIC Levels of Linezolid
8.09
In Vivo Activities
of Linezolid, a Novel Oxazolidinone Antimicrobial Agent
Against Experimental Bacterial Infections
8.10
Antimicrobial Effects
of Linezolid and Vancomycin in Experimental Endocarditis
8.11
Linezolid (L) vs Methicillin-Resistant
Staphylococcus aureus (MRSA) in Experimental Rat Endocarditis
(E)
8.12
In Vitro Activity
of Macrolide, Azalide, Ketolide, and Oxazolidinone Antimicrobials
vs. Dog and Cat Bite Pathogens (POSTER AVAILABLE)
8.13
In Vitro Activities
of the Oxazolidinones Eperezolid and Linezolid against
Bordetella pertussis and Bordetella parapertussis
8.14
Linezolid: Antibiotic
Susceptibility and Intracellular Activity Against Legionella
spp.
8.15
In Vitro Activity
of Linezolid Against Multiple Species of Nocardia: A New
Drug of Choice for a Difficult Disease?
8.16
Pharmacodynamic Activity
of a New Oxazolidinone, Linezolid, in an Animal Infection
Model
8.17
Pharmacokinetics of
Linezolid in Patients With Liver Disease
8.18
Pharmacokinetics of
Linezolid in Subjects With Varying Degrees of Renal Function
and on Dialysis
8.19
Effect of Age and
Gender on the Single-Dose Pharmacokinetics of Linezolid
8.20
Linezolid Safety,
Tolerance, and Pharmacokinetics After Intravenous Dosing
Twice Daily for 7.5 Days
8.21
Linezolid Safety,
Tolerance, and Pharmacokinetics Following Oral Dosing
Twice Daily for 14.5 Days
8.22
Efficacy of Linezolid
in Community-Acquired S. pneumoniae Pneumonia
8.23
Safety and Tolerance
of Linezolid in Phase II Trials
8.24
Results of Treating
Bacteremic Patients with Linezolid in a Compassionate
Use Trial for Resistant, Gram-Positive Infections
8.25
Efficacy of Linezolid
in Skin and Soft Tissue Infections
8.26
Safety and Efficacy
of Linezolid (PNU-100766) in Eradication of Nasal Staphylococcus
aureus
GROUP
9
Pharmacology, Pharmacokinetics and Pharmacodynamics
of the MASKO Compounds
9.01
Bacterial Killing
by Macrolides: Concentration-Dependent or Time-Dependent? (POSTER AVAILABLE)
9.02
Serum Bactericidal
Activity of Clarithromycin Against Isolates of Streptococcus
Pneumoniae
9.03
In Vitro Comparative
Dynamics of Roxithromycin, Clarithromycin- and Azithromycin
for Activity and Susceptibility
9.04
In Vitro Comparative
Dynamics of Clarithromycin Modified Release (MR) and Azithromycin (POSTER AVAILABLE)
9.05
Azithromycin Dosage
Regimen Evaluation by Means of a Pharmacokinetics/ Pharmacodynamics
Simulation Program
9.06
Is There a Major Lack
of Azithromycin Concentration in Tonsils After Omitted
Doses? Contribution of a Simulation Program
9.07
The Effect of Food
on an Oral Azithromycin Syrup Formulation
9.08
Lack of Food Effect
on the Bioavailability of Oral Azithromycin Tablets (POSTER AVAILABLE)
9.09
Comparison of Pharmacokinetics
of Oral Azithromycin and its 12-0-Methyl Derivative in
Mice (POSTER AVAILABLE)
9.10
Plasma Profiles of
Two Azithromycin Derivatives After Single Oral Administration
in Rats (POSTER AVAILABLE)
9.11
Azithromycin can Safely
Be Used in Combination with Cyclosporin for the Treatment
of Respiratory Tract Infections in Renal Transplant Patients (POSTER AVAILABLE)
9.12
The Bioavailability
of Two Oral Azithromycin Formulations in Healthy Male
Volunteers (New Analytical Method) (POSTER AVAILABLE)
9.13
Pharmacokinetics of
Azithromycin Oral Suspension Following 12 mg/kg/day (Maximum
500 mg/day) for 5 Days in Fed Pediatric Patients (POSTER AVAILABLE)
9.14
Update on the Drug
Interaction Profile of Azithromycin (POSTER AVAILABLE)
9.15
Serum and WBC Exposures
of Azithromycin (AZ) Given as Either a Single (SD) or
Three Day (TD) Regimen (POSTER AVAILABLE)
9.16
A Survey of the Quality
of Generic Clarithromycin Products from 13 Countries (POSTER AVAILABLE)
9.17
Oral Clarithromycin
Absorption in Patients with Community Acquired Pneumonia
9.18
Pharmacokinetics of
a New Extended-Release Clarithromycin Tablet at Doses
of 500 and 1000 mg Daily (POSTER AVAILABLE)
9.19
A New Bioassay for
the Measurement of Synercid and its Components (Quinupristin
and Dalfopristin) in Sera
9.20
Impact of Quinupristin/dalfopristin
(RP59500) on the Fecal Microflora in Healthy Volunteers
9.21
Pharmacokinetics of
800-mg Once-Daily Oral Dosing of the Ketolide Telithromycin
(HMR 3647), in Healthy Young Volunteers
9.22
Dose Proportionality
of the Pharmacokinetics of Telithromycin (HMR 3647), a
New Ketolide Antimicrobial, in Healthy Adult Males
9.23
Pharmacokinetic Profile
of Telithromycin (HMR 3647) 800 mg Once-Daily in Elderly
Volunteers
9.24
The Bioavailability
of Telithromycin (HMR 3647), a New Once-Daily Ketolide
Antimicrobial, is Unaffected by Food
9.25
Treatment of Genital
Chlamydial Infections with Roxithromycin
9.26
Telithromycin (HMR
3647) Achieves High and Sustained Concentrations in Bronchopulmonary
Tissues
9.27
Telithromycin (HMR
3647) Achieves High and Sustained Concentrations in White
Blood Cells in Man
9.28
Cytochrome P450 (CYP-450)
Activity is Not Inhibited In Vitro by Telithromycin (HMR
3647), a New Ketolide Antimicrobial
9.29
Telithromycin (HMR
3647), a New Ketolide Antimicrobial, Does Not Affect the
Reliability of Low-Dose, Triphasic Oral Contraceptives
9.30
Telithromycin (HMR
3647), a New Ketolide Antimicrobial, Does Not Affect the
Pharmacodynamics or Pharmacokinetics of Warfarin
9.31
Telithromycin (HMR
3647), a New Ketolide Antimicrobial, is Metabolised and
Excreted Mainly in Faeces in Man
9.32
In Vitro and In Vivo
Metabolism of [14C]ABT-773
9.33
Pharmacokinetics of
ABT-773 in Mouse, Rat, Monkey and Dog
GROUP
10
Highlights of Research on H. Pylori
10.01
Specificity and Performance
of TestPack Plus H. pylori Office-Based Serology Compared
to Endoscopy, UBT, and FlexPack HP (POSTER AVAILABLE)
10.02
Antimicrobial Resistance
of Helicobacter pylori (POSTER AVAILABLE)
10.04
Sensitivity of Helicobacter
pylori to Eight Antibiotics (POSTER AVAILABLE)
10.05
Primary Resistance
of Helicobacter pylori to Macrolides and Metronidazole (POSTER AVAILABLE)
10.06
No Progression of
Primary Azithromycin and Clarithromycin Resistance and
Progression of Primary Metronidazole Resistance in Clinical
Isolates of Helicobacter pylori in Croatia (POSTER AVAILABLE)
10.07
In Vitro Activity
of ABT-773 (ABT), a New Ketolide Antibiotic, Alone and
in Combination with Metronidazole (MET), Amoxicillin (AMO),
or Tetracycline (TTC) Against Helicobacter pylori (POSTER AVAILABLE)
10.08
In Vitro Activity
of Clarithromycin and Metronidazole Against Helicobacter
pylori by Using Different Incubation Atmosphere
10.09
Importance of Minimum
Inhibitory Concentrations Levels on Helicobacter pylori
Eradication Using Omeprazole, Clarithromycin and Amoxicillin
in Pediatric and Adult Populations
10.10
Croatian Helicobacter
pylori Study Group (CHPSG): Recommendation for Helicobacter
pylori Treatment (Poster Available)
10.11
Eradication of Helicobacter
pylori Infection with Four One-Week Triple Therapy Regimens
Containing Azithromycin (POSTER AVAILABLE)
10.12
Low Dose Azithromycin
vs High Dose Azithromycin in Ranitidine Bismuth Citrate
(RBC) Based Triple Therapies for Helicobacter pylori Eradication (POSTER AVAILABLE)
10.13
10-Day Triple Therapy
with Lanzoprazole, Clarithromycin, and Amoxicillin for
H. pylori Eradication in Duodenal Ulcer Disease
10.14
Azithromycin and
Ranitidine Bismuth Citrate With/Without Amoxicillin for
Helicobacter pylori Eradication (POSTER AVAILABLE)
10.15
Once-Daily H. pylori
Treatment to Family Members of Gastric Cancer Patients
10.16
Concentrations of
Roxithromycin and Clarithromycin in Gastric Mucosa of
Patients during H. pylori Eradication Therapy
10.17
Secondary Helicobacter
pylori Resistance to Azithromycin and/or Metronidazole
after Treatment Failure (POSTER AVAILABLE)
10.18
Study of Virulence
Factors Affecting Eradication with Omeprazol, Clarithromycin
and Amoxicillin in Two Different Populations (Children
and Adults) Infected with Helicobacter pylori
GROUP
11
Expanding the Potentials for the MASKO Compounds: Asthma,
Atherosclerosis, Cancer and Inflammation
11.01
Chlamydia pneumoniae
Asthma Roxithromycin Multinational (CARM) Study
11.02
Importance of Mycoplasma
pneumoniae and Chlamydia pneumoniae Acute Infection in
Children with Recurrent Wheezing (POSTER AVAILABLE)
11.03
Incidence of Macrolide-Resistant
Mycobacterium avium Complex (MAC) Breakthrough Infection
in Patients Receiving Prophylaxis Against Disseminated
MAC Disease
11.04
The Effect of Short-Term
Clarithromycin on Airway Hypersecretion in Chronic Airway
Diseases
11.05
Placebo Controlled
Trial Evaluating the Efficacy of Clarithromycin (CLA)
in Patients with Corticosteroid-Dependent Asthma (POSTER AVAILABLE)
11.06
Asthma, Chlamydia
pneumoniae and Roxithromycin
11.07
Infection with Chlamydia
pneumoniae Accelerates the Development of Atherosclerosis
and Treatment with Azithromycin Prevents it in a Rabbit
Model (POSTER AVAILABLE)
11.08
Double-Blind, Placebo-Controlled
Multicenter Study of the Effects of Azithromycin in C.
pneumoniae Positive Post-Myocardial Infarction Patients
(CROAATS): Study Announcement (POSTER AVAILABLE)
11.09
Clarithromycin Modulates
the Production of Cytokines in Lung Cancer Patients
11.10
Chlamydia pneumoniae,
Coronary Heart Disease, and Azithromycin: Where Do We
Stand? (POSTER AVAILABLE)
11.11
Differential Cytokine
Release with Antimicrobials against Streptococcus pneumoniae
in Whole Blood (POSTER AVAILABLE)
11.12
Induction of Apoptosis
in Murine Myeloma by Clarithromycin
11.13
Erythromycin Inhibits
Immune Complex-Induced Lung Injury: Role of Nitric Oxide
from Alveolar Macrophages (POSTER AVAILABLE)
11.14
Erythromycin Inhibits
LPS Induced Inflammation in Rats (Poster Available)
11.15
In Vitro and In Vivo
Influence of Adjunct Clarithromycin on the Treatment of
Mucoid Pseudomonas aeruginosa (POSTER AVAILABLE)
11.16
Beneficial Effect
of Adjunctive Azithromycin in the Treatment of Mucoid
Pseudomonas aeruginosa Pneumonia (POSTER AVAILABLE)
11.17
Anti-Inflammatory
Effects of Clarithromycin in a Murine Model of Lung Eosinophilia
and Mucus Production (POSTER AVAILABLE)
11.18
Macrolides Inhibit
Mucus Secretion in the Inflamed Ferret Trachea (POSTER AVAILABLE)
11.19
Effects of Clarithromycin
on Human Neutrophil Chemotaxis, Phagocytosis and Oxygen
Radical Generation In Vitro
11.20
Mycoplasma and Chlamydia
are Present in the Airways of Chronic, Stable Asthmatics (POSTER AVAILABLE)
11.21
Improvement of Clinical
Signs and Symptoms of Chronic Inflammatory Sinusitis With
Clarithromycin (POSTER AVAILABLE)
11.22
Anti-inflammatory
Activity of Clarithromycin in the Treatment of Adults
With Chronically Inflamed Sinus Mucosa (POSTER AVAILABLE)
|
|
A B C
D E F G
H I
J K L M
N O P Q
R
S T U V
W X Y
Z
A
Adam, D.
6.06
Akamatsu, H.
11.19
Alarcon, T.
10.08
Aljinovic, V.
5.01
6.05
Alvarez, M.
4.42
Amsden, G.
9.14
9.15
Andes, D.
8.16
Andruschenko, E.
4.03
Appelbaum, P.
2.21
8.07
Ashraf, T.
4.11
4.12
4.19
9.16
B
Bace, A.
6.20
Ballow, C.
1.08
1.09
1.10
Barry, A.
2.12
Barsic, B.
5.25
5.28
Batts, D.
8.18
8.22
8.23
8.25
Bebear, C.
2.35
Beghi, G.
4.32
Bennish, M.
5.16
Bermudez, L.
3.16
Betica-Radic, L.
7.19
Bettig, U.
4.33
Beus, A.
5.15
Bevan, C.
5.33
Bingen, E.
7.13
Birmingham, M.
8.24
Brown, B.
8.15
Brown, S.
1.19
2.07
Butler, T.
1.21
C
Calkic, L.
6.19
Casellas, J., Sr.
1.22
Chidiac, C.
4.21
Citron, D.
2.29
Cizvman, M.
7.01
Cocuzza, C.
1.16
Coelho, L.
10.13
10.15
Coles, S.
6.09
Craft, J.
3.07
7.04
Culig, J.
5.22
11.08
Cynamon, M.
3.14
D
DšAndrea Marcolino, F.
4.09
Danziger, L.
2.25
2.26
2.34
10.07
11.11
Declercq, P.
1.12
Derek, M.
1.01
Di Modugno, E.
7.06
7.14
Domingo, D.
10.09
Dominis-Kramaric, M.
9.09
Douthwaite, S.
2.01
2.02
Drugeon, H.
9.19
Dubois, J.
2.15
2.33
3.08
Dudas, V.
4.26
4.27
E
Elies, W.
4.07
Erceg, D.
9.10
9.12
Esposito, S.
6.27
11.02
F
Fedeli, F.
5.08
Falleiros-Carvalhow, L.
6.03
Felmingham, D.
2.23
7.02
Fernandez-Obregon, A.
5.31
Ferrer, I.
7.24
Figueira, M.
3.09
Finegold, S.
2.30
2.36
Fines, M.
8.02
Firsov, A.
3.01
Flamm, R.
2.04
7.07
Focht, J.
1.14
Ford, C.
8.09
Fraschini, F.
9.04
Frenck, R.
6.30
G
Galiana, A.
6.29
Gemmell, C.
8.08
Gendrel, D.
6.26
Giamarellou, H.
2.11
Gibson, J.
8.10
Giugno, E.
4.16
Goldstein, E.
2.31
Gooch, W.
6.14
Gotfried, M.
4.05
11.05
Georgopoulos, A.
1.17
Graham, D.
5.10
Gray, S.
5.04
5.05
Gruber, F.
5.30
Guggenbichler, J.
6.01
Gustavson, L.
9.18
Gutierrez, J.
6.16
H
Hamid, Q.
11.22
Hammerschlag, M.
2.32
3.03
Hernandez, L.
9.33
Hoban, D.
2.27
Hoppe, J.
8.13
Horvat, R.
4.01
Hyatt, J.
3.02
8.26
I
lannini, P.
7.22
Inderlied, C.
11.03
J
Jankoska, J.
1.23
Jarcuska, P.
4.02
Jewell, M.
4.28
4.29
Jones, R.
8.01
Jungbluth, G.
8.17
8.19
8.20
8.21
K
Kahn, J.
4.24
Kalenic, S.
1.13
Kaltenis, P.
6.07
Karpov, O.
4.13
Katicic, M.
10.05
10.11
10.14
Kemper, C.
6.22
King, S.
11.17
Kislak, J.
1.24
Kita, E.
11.12
Krings, D.
4.08
4.14
4.22
Kuzman, I.
4.45
L
Langford, J.
11.01
Langsádl, L.
1.18
Lebel, M.
6.21
Lellei, I.
6.10
Lenfant, B.
9.21
9.22
9.23
9.24
9.26
9.27
9.28
9.31
Le Normand, Y.
9.05
9.06
Lin, J.
9.32
Linden, P. 5.07 5.07
Loeffler, A.
6.04
Lonks, J.
7.09
Lopez-Brea, M.
10.18
Low, D.
7.20
7.21
M
Ma, Z.
2.03
Macleod, C.
6.15
10.01
Mankin, A.
1.02
8.04
Maretic, T.
5.29
Marklein, G.
1.07
Marrie, T.
4.48
Martin, R.
11.20
Martinez-Sahuquillo, A.
5.20
Mattina, R.
6.17
Mauriz, Y.
7.12
Mauvais, P.
2.10
McKinnon, P.
4.37
Mikasa, K.
11.09
Mitten, M.
3.10
3.11
3.12
Muhlestein, J.
11.07
11.10
Music, E.
4.46
N
Nicolau, D.
11.15
11.16
Nicoletti, G.
8.03
Nilius, A.
2.05
2.16
2.18
2.24
Noskin, G.
8.05
Notario, G.
4.25
5.18
Novak, D.
9.11
Novelli, A.
9.01
O
Ohrt, C.
5.32
Oreskovic, K.
5.26
Overturf, G.
6.23
P
Paladino, J.
4.39
Palmer, R.
4.15
Pankuch, G.
2.09
Panovski, N.
1.03
Papa, B.
10.10
Patton, D.
3.05
Petersen, E.
9.25
Pfrunder, D.
3.04
4.31
7.03
Pitsakis, P.
8.11
Plecko, V.
10.06
10.17
Plouffe, J.
4.38
4.47
Pontani, D.
4.41
4.43
Portillo, A.
7.16
Principi, N.
6.28
R
Radonic, M.
7.05
Ramilo, O.
3.13
Ramos, P.
11.06
Rapp, R.
4.36
Rehm, S.
5.06
Retsema, J.
7.10
Revillo, M.
7.25
10.02
Robredo, B.
7.17
Rubin, B.
11.18
Rusiec-Pavletic
11.14
S
Sabath, L.
5.12
5.13
Sanchez, S.
4.10
Scaglione, F.
9.03
Scanvic-Hameg, A.
9.20
Schachter, J.
5.27
Schwarck, H.
5.14
10.16
Sesartic, P.
4.34
Shillington, A.
4.30
4.44
Shortridge, D.
1.06
1.15
2.06
2.17
2.19
2.20
2.28
4.17
4.18
Simicevic, V.
9.07
9.08
Simko
5.21
Singh, K.
2.14
Siwinski-Golebiowska, H.
6.13
Slapák
6.12
Sommer, A.
6.02
Sopena, N.
4.40
Speciale, A.
1.11
Srinath, L.
5.09
5.11
Stein, G.
9.02
Steiner, F.
6.25
Sterk-Kuzmanovic, N.
1.04
Stratchounski, L.
1.20
6.08
6.18
Strle, F.
5.02
Summersgill, J.
8.14
Sutcliffe, J.
2.13
2.22
Synopalnikov, A.
4.04
T
Tagaya, E.
11.04
Talan, D.
8.12
Tamaoki, J.
11.13
Tepec, B.
10.04
Thadepalli, H.
3.06
Thakker, K.
9.13
Traczewski, M.
2.08
Treadway, G.
5.03
6.11
Tremblay, C.
11.21
Triana, T.
6.24
V
Vacheron, F.
9.29
9.30
Vanjaka, A.
9.17
Vincken, W.
4.20
Vouillamoz, J.
3.15
7.18
Vucelic, B.
10.12
W
Waites, K.
7.08
Wallace, R., Jr.
4.06
Wang, J.
5.24
Weiss, K.
1.05
7.15
7.23
Wiesinger, B.
4.23
Z
Zhanel, G.
7.11
8.06
Zilevica, A.
5.23 |
|
|
